Background Platelet inhibition is mandatory therapy after percutaneous coronary
intervention (PCI). Withdrawal of oral antiplatelet agents has been linked to increased …

Physicians commonly encounter patients undergoing noncardiac surgery who have
previously received a coronary artery stent. 1 Several large observational studies have …

Background Perioperative discontinuation of antiplatelet therapy (APT) in patients with
coronary stents has been associated with major adverse cardiac events. Our aim was to …

Up to 11% of patients presenting with acute coronary syndromes undergo coronary artery
bypass grafting. Guidelines largely recommend a one-size-fits-all preoperative …

The management of coronary patients scheduled for a coronary artery bypass grafting
(CABG), who are receiving one or more antiplatelet drugs, is plenty of controversies. It has …

Background and objectiveBleeding after cardiac surgery correlates with morbidity and
mortality. The aim of this study was to determine the influence of antiplatelet therapy on …

Nearly 20% of patients will need non-cardiac surgery within 1 year of coronary stenting and
their management is complicated by concomitant antiplatelet therapy. Platelet function …

To the Editor: Noncardiac surgery early after percutaneous coronary intervention (PCI) with
stenting has been associated with adverse cardiac events in the perioperative period (1, 2) …

Noncardiac surgery (NCS) may be required within the first year after percutaneous coronary
intervention (PCI) in approximately 4% of patients and is the second most common reason …

Perioperative cardiovascular complications are important causes of morbidity and mortality
associated with non-cardiac surgery, especially in patients with recent percutaneous …